EUVIMEDEUVIMED entdecken
Crossref

Outcomes with low dose anti‐thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation

Hafsah Chalchal, Vinita Dhir, Ashish Masurekar, Harold Atkins, Christopher Bredeson, Michael Kennah, Natasha Kekre, David Allan, Ram Vasudevan Nampoothiri

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Hafsah Chalchal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ontario, Ottawa, Canada. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Unrelated Donors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti‐thymocyte globulin (ATG) based graft versus host disease (GVHD) prophylaxis is widely used for mismatched unrelated donor allogeneic hematopoietic cell transplantation (HCT) although optimal dose remains unclear. Although recent literature suggested improved outcomes with PTCy‐based regimens when compared to ATG‐based regimens these studies used doses of ATG ≥5 mg/kg. Thus, we analyzed outcomes of HLA 9/10 MMUD allogeneic HCTs using lower‐dose ATG‐based regimens at our center.

Methods

We retrospectively analyzed outcomes of HLA 9/10 MMUD allogeneic HCTs using lower dose ATG‐based regimens for all adults undergoing allogeneic HCT at The Ottawa Hospital from 2015 to 2022. Data regarding demographics, conditioning regimen, dose of ATG, rates of GVHD, duration of remission, and survival, were collected and analyzed.

Results

Seventy‐seven ( n = 77) patients (males 62.3%; median age 50 years) underwent allogeneic HCT from MMUD. Majority(81%; n = 63) received 2.5 mg/kg of rabbit ATG and remaining 18.2% ( n = 14) received 4.5 mg/kg. Grade II‐IV acute GVHD occurred in 24.7% ( n = 19) while any chronic GVHD occurred in 32.5% ( n = 25) patients. After a median follow‐up of 21 months, relapse occurred in 28.6% of patients. Two‐year OS, GRFS, CIR, and NRM were 60.6%, 45.3%, 16.9%, and 18.2% respectively. Dose of ATG (2.5 mg/kg vs. 4.5 mg/kg) was not associated with outcomes in either univariate or multivariate analyses.

Conclusions

When compared to published studies using ATG doses ≥5 mg/kg, GVHD prophylaxis using lower dose ATG may potentially lead to improved outcomes in patients undergoing MMUD allogeneic HCT. Further studies are needed to directly compare lower dose ATG to PTCy‐based regimens to determine ideal GVHD prophylaxis for these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antilymphocyte SerumGraft vs Host DiseaseHematopoietic Stem Cell TransplantationUnrelated DonorsTransplantation, HomologousTransplantation ConditioningHumansMaleMiddle AgedFemaleAdultRetrospective StudiesTreatment OutcomeAgedHistocompatibilityYoung AdultHistocompatibility Testing

Stichwörter der Autor:innen

GVHD prophylaxisallogeneic stem cell transplantationlow dose anti‐thymocyte globulinmismatched unrelated donor

Substanzen

Antilymphocyte Serum

Autor:innen und Institutionen

  • Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ontario, Ottawa, Canada.

Zitieren

APA

Chalchal, H., Dhir, V., Masurekar, A., Atkins, H., Bredeson, C., Kennah, M., Kekre, N., Allan, D., & Vasudevan Nampoothiri, R. (2024). Outcomes with low dose anti‐thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation. European Journal of Haematology. https://doi.org/10.1111/ejh.14274

Vancouver

Chalchal H, Dhir V, Masurekar A, Atkins H, Bredeson C, Kennah M, et al. Outcomes with low dose anti‐thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation. European Journal of Haematology. 2024. doi:10.1111/ejh.14274

BibTeX
@article{Chalchal2024,
  author = {Chalchal, Hafsah and Dhir, Vinita and Masurekar, Ashish and Atkins, Harold and Bredeson, Christopher and Kennah, Michael and Kekre, Natasha and Allan, David and Vasudevan Nampoothiri, Ram},
  title = {Outcomes with low dose anti‐thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14274}
}
Kostenlos starten →